Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.
The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.
The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.
Total raised: $88.41M
Investors 5
| Date | Name | Website |
| 18.03.2022 | Jeito Capi... | jeito.life |
| - | V-Bio Vent... | v-bio.vent... |
| 22.03.2022 | Forbion | forbion.co... |
| 16.06.2022 | GIMV | gimv.com |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2022 | Series B | $88.41M | Jeito Capi... |
Mentions in press and media 17
| Date | Title | Description |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 16.06.2025 | Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology | New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global ... |
| 14.09.2022 | Precirix enters into collaboration with Eckert & Ziegler for the development of its 68Ga-based compounds | Brussels, Belgium and Berlin, Germany, 12 September 2022 – Precirix NV and Eckert & Ziegler Eurotope GmbH (Eckert & Ziegler) have signed a collaboration agreement for the development of a highly reliable and efficient automated prod... |
| 09.08.2022 | Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225 | Brussels, Belgium and Berlin, Germany, 26 July 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, and Eckert & Ziegler (ISIN DE0005659700, SDAX) have signed an agreement for... |
| 10.06.2022 | Precirix presents preclinical data of its FAP-targeting compound at the SNMMI annual meeting | Brussels, Belgium, 10 June 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, will present preclinical data of its FAP-targeting single domain antibody (sdAb) linked to multiple... |
| 31.05.2022 | Precirix strengthens patent portfolio of its precision radiopharmaceuticals platform | Brussels, Belgium, 31 May 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today provides an update on its patent portfolio that has been strengthened with newly granted paten... |
| 17.03.2022 | Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals | Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capit... |
| 17.03.2022 | Precirix picks up €80M Series B | Precirix has raised €80 million in a round co-led by Jeito Capital, Forbion and Inkef Capital. The Belgian clinical-stage biotech company develops precision radiopharmaceuticals in oncology. View details |
| 17.03.2022 | Precirix Raises €80M in Series B Funding | Precirix NV, a Brussels, Belgium-based clinical-stage biotechnology company, raised €80M in Series B funding. The round was led by INKEF Capital, Jeito Capital and Forbion. The company’s existing shareholders Gimv, HealthCap, Novo Holdings,... |
| 17.03.2022 | Belgian biotech company Precirix secures €80M from Amsterdam-based INKEF Capital, others | Brussels-based Precirix, a platform developing radio-immunotherapeutic drugs for cancer patients, announced on Wednesday that it has raised €80M in its Series B round of funding. The round was led by new investors INKEF Capital, Jeito Capit... |
Show more